Access recorded conference sections presented by local and international experts
Safety of testosterone replacement therapy
35th Congress of the Israeli Urological Association, November 25, 2015
Hypogonadism does not exist in isolation. In this presentation Dr. Saad highlights that men with hypogonadism often present with multiple comorbidities, especially obesity, diabetes, cardiovascular disease and osteoporosis. Following this, Dr. Saad presents compelling research data that refutes the common misperceptions about testosterone therapy and its supposed negative effects on cardiovascular disease and prostate cancer. In contrast to common belief, data suggests that testosterone therapy has beneficial effects on both cardiovascular disease and prostate outcomes.
Prof. h.c. Dr. Farid Saad, Global Medical Affairs Andrology, Bayer Pharma AG, Berlin, Germany, Gulf Medical University, Research Department, Ajman, United Arab Emirates, and Hang tuah University, Men's Health Reproduction Study Center, Surabaya, Indonesia